Latest News

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application
2026-09-09

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application

On 9 September, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.   Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, […]

Learn More
CMS Charity | Supporting Each Other Through Adversity: CMS Donated RMB 1 Million to Support Debris-Flow-Hit Area in Gyirong, Tibet
2026-09-03

CMS Charity | Supporting Each Other Through Adversity: CMS Donated RMB 1 Million to Support Debris-Flow-Hit Area in Gyirong, Tibet

On 26 August 2026, a large-scale ice-rock avalanche in Nepal triggered a debris flow that struck Gyirong Port in Gyirong County, Shigatse, Tibet, resulting in significant casualties, missing persons and infrastructure damage. The sudden disaster has drawn widespread concern for the safety and well-being of those affected. In response, China Medical System Holdings Limited (CMS) acted swiftly to support emergency relief and recovery efforts, donating RMB 1 million in cash through the Tibet Autonomous Region Charity Federation to the disaster-affected areas of Gyirong County, Shigatse, Tibet. The donation will support emergency rescue operations, resettlement for affected residents and post-disaster reconstruction, providing tangible support to frontline responders and the basic living needs of the affected population. The pharmaceutical industry was born out of the need to save lives, and it gains its humanity through its commitment to protecting them. Guided by its founding commitment to “fulfill social responsibility and safeguard life and health,” CMS […]

Learn More
CMS: Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
2026-09-03

CMS: Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

Second indication approved: As the first topical JAK inhibitor approved in China for the treatment of vitiligo, Lumirix®has received China approval for the additional indication of atopic dermatitis (AD), offering a novel treatment option for pediatric patients 2 years of age and older, adolescent and adult AD patients, with safety and efficacy supported by clinical data*.  Impressive Phase III AD data in China: At week 8, 63.0% of subjects achieved IGAof 0 or 1 with at least two grades of reduction from baseline, versus 9.2% for placebo; 78.0% of subjects achieved EASI 75, versus 15.4% for placebo. A comprehensive AD “treatment + care” solution: Dermavon has developeda professional AD treatment-and-care portfolio comprising Lumirix® (topical formulation, mild-to-moderate AD), Comekibart Injection (injectable biological agent, moderate-to-severe AD), CMS-D001 (oral small molecule targeted drug, moderate-to-severe AD), and the Heling Soothing Product Series (daily repair).   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China, Accelerating Clinical Application
2026-09-09
CMS Charity | Supporting Each Other Through Adversity: CMS Donated RMB 1 Million to Support Debris-Flow-Hit Area in Gyirong, Tibet
2026-09-03
CMS: Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
2026-09-03
Dual Growth in Turnover and Profit | CMS (867.HK, 8A8.SG) 2026 Interim Performance Report in One Picture
2026-08-17
Secretary of the CPC Hainan Provincial Committee Feng Fei Visits Dermavon Hainan
2026-08-11
CMS: Rxilient Obtained Commercialization Rights for Dermatology Improved New Drug Finjuve and Branded Drug Ciclopoli in Southeast Asia and Other Markets
2026-07-27
Dual ESG Recognition: CMS Named Among “China ESG Leaders 2026” and Honored with the “Green Supply Chain Leadership Award”
2026-07-17
China Medical System: Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is Approved for Drug Clinical Trials for Age-related Macular Degeneration
2026-07-15
CMS Charity | Standing Together with Guangxi: Medical Supplies Worth Over RMB 1 Million Rushed to Disaster Areas
2026-07-13
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
2026-06-22